Cargando…

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab

Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by uncontrolled terminal complement activation and subsequent intravascular hemolysis (IVH). C5 inhibitors prevent membrane attack complex formation, but patients may experience extravascular hemolysis (EVH) and continue to require blood tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulasekararaj, Austin G., Risitano, Antonio M., Maciejewski, Jaroslaw P., Notaro, Rosario, Browett, Peter, Lee, Jong Wook, Huang, Mingjun, Geffner, Michael, Brodsky, Robert A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602931/ https://www.ncbi.nlm.nih.gov/pubmed/34314483 http://dx.doi.org/10.1182/blood.2021011388

Ejemplares similares

Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
por: Risitano, Antonio M., et al.
Publicado: (2020)

P771: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD-ON DANICOPAN VS PLACEBO
por: Wook Lee, Jong, et al.
Publicado: (2023)

Low-dose prednisolone in patients with paroxysmal nocturnal hemoglobinuria and inadequate response to eculizumab
por: Moon, Ji Young, et al.
Publicado: (2017)

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
por: de Castro, Carlos, et al.
Publicado: (2020)

Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
por: Brodsky, Robert A., et al.
Publicado: (2020)

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009)

Biosimilars in rare diseases : a focus on paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin, et al.
Publicado: (2022)

Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond Siu Ming, et al.
Publicado: (2023)

The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin G., et al.
Publicado: (2022)

Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation
por: Brodsky, Andrés, et al.
Publicado: (2012)

Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study
por: Jang, Jun Ho, et al.
Publicado: (2022)

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT
por: Risitano, Antonio M., et al.
Publicado: (2019)

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations
por: Al-Ani, Fatimah, et al.
Publicado: (2016)

Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report
por: Fassett, Michael J., et al.
Publicado: (2021)

Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?
por: Bellido, M., et al.
Publicado: (2012)

Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria
por: Kawakami, Toru, et al.
Publicado: (2017)

Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report
por: Quinquenel, Anne, et al.
Publicado: (2017)

Effect of Eculizumab on Iron Metabolism in Transfusion-independent Patients With Paroxysmal Nocturnal Hemoglobinuria
por: Schaap, Charlotte C.M., et al.
Publicado: (2023)

Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
por: Quist, S. W., et al.
Publicado: (2023)

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
por: Hillmen, Peter, et al.
Publicado: (2013)

One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab
por: Kulasekararaj, Austin G., et al.
Publicado: (2021)

The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
por: Kim, Jin Seok, et al.
Publicado: (2010)

Successful use of eculizumab in an 86-year-old patient with paroxysmal nocturnal hemoglobinuria in Japan
por: Ooe, Yokiko, et al.
Publicado: (2014)

Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report: Erratum
Publicado: (2017)

Eculizumab-Related Abortion in a Woman with Paroxysmal Nocturnal Hemoglobinuria: A Case Report
por: Rodríguez-Ferreras, Adrián, et al.
Publicado: (2019)

Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria
por: Schwartz, Carolyn E., et al.
Publicado: (2021)

COVID-19 Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy
por: Barcellini, Wilma, et al.
Publicado: (2020)

Prolonged Remission of Cancer of Unknown Primary following Initiation of Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria
por: Lim, Ming Y., et al.
Publicado: (2019)

Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report
por: Alexopoulou, Alexandra, et al.
Publicado: (2019)

Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report
por: Füreder, Wolfgang, et al.
Publicado: (2020)

The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria
por: Lazana, Ioanna, et al.
Publicado: (2023)

PB2059: SENSITIVITY AND SUBGROUP ANALYSES FURTHER SUPPORT CLINICAL SIMILARITY IN EFFICACY BETWEEN ABP 959 AND ECULIZUMAB REFERENCE PRODUCT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Kulasekararaj, Austin, et al.
Publicado: (2023)

Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria
por: Gurnari, Carmelo, et al.
Publicado: (2021)

Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin, et al.
Publicado: (2022)

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
por: Peipert, John Devin, et al.
Publicado: (2020)

Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents
por: Risitano, Antonio M, et al.
Publicado: (2008)

Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going
por: Risitano, Antonio M
Publicado: (2014)

Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria
por: Ninomiya, Haruhiko, et al.
Publicado: (2015)

Long Standing Eculizumab Treatment without Anticoagulant Therapy in High-Risk Thrombogenic Paroxysmal Nocturnal Hemoglobinuria
por: Al-Jafar, Hassan A., et al.
Publicado: (2015)

Preoperative administration of eculizumab to prevent surgery‐triggered hemolysis during cesarean section with paroxysmal nocturnal hemoglobinuria
por: Li, Dongping, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vgkgbrpohe5cv9ivnm9h86kqst